In summary, the findings reported here show that TH1834 administration on days 3-16 post-MI mimics the functional benefits of genetically depleting Tip60, which is accompanied by diminished scarring, enhanced CM cell-cycle activation, reduced CM apoptosis and increased CM density, effects that are in accordance with reduced expression of genes that promote apoptosis and inhibit the cell cycle. The gene discussed is KAT5; the disease is myocardial infarction.